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Bacterial cancer therapy is a concept more than 100 
years old — yet, all things considered, it is still in early 
development. While the use of many passive therapeu-
tics is hindered by the complexity of tumor biology, bac-
teria offer unique features that can overcome these limi-
tations. Microbial metabolism, motility and sensitivity 
can lead to site-specific treatment, highly focused on the 
tumor and safe to other tissues. Activation of tumor-spe-
cific immunity is another important mechanism of such 
therapies. Several bacterial strains have been evaluated 
as cancer therapeutics so far, Salmonella Typhimurium 
being one of the most promising. S. Typhimurium and 
its derivatives have been used both as direct tumoricidal 
agents and as cancer vaccine vectors. VNP20009, an at-
tenuated mutant of S. Typhimurium, shows significant 
native toxicity against murine tumors and was studied 
in a first-in-man phase I clinical trial for toxicity and an-
ticancer activity. While proved to be safe in cancer pa-
tients, insufficient tumor colonization of VNP20009 was 
identified as a major limitation for further clinical devel-
opment. Antibody-fragment-based targeting of cancer 
cells is one of the few approaches proposed to over-
come this drawback.
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INTRoducTIoN
It was at the end of the 19th century that bacteria were 
for the first time intentionally applied for cancer treat-
ment. William Coley, a bone sarcoma surgeon at the Me-
morial Hospital in New York, having conducted a thor-
ough literature search, found 47 well-documented cases 
of beneficial influence of serious bacterial infections in 
tumor patients (McCarthy, 2006). On the basis of the 
then-available data he concocted a mixture of killed 
Streptococcus pyogenes and Serratia marcescens bacteria, which 
became known as Coley’s toxin. Over the next forty 
years Coley applied his toxin to almost 1000 patients 
who suffered from various types of inoperable cancers. 
Striving to improve the effectiveness of the therapy, he 
used various doses of his toxin, different regimens and 
durations of treatment, as well as different routes of ap-
plication and therefore it is difficult to fully comprehend 
his enormous work. In many cases several-month treat-
ment resulted in complete tumor regression. The five-
year survival period for patients suffering from inoper-
able carcinomas ranged from 34 to 73%, and for those 
suffering from inoperable sarcomas was in the range 
between 13 and 79%, varying with the tumor subtype 
(Green & Hoption Cann, 2007). However, the results of 
Coley’s treatment have been non-reproducible, uncertain, 
and unpredictable and therefore his therapy often met 
with strong criticism from the medical community. At 
the beginning of the 20th century it was gradually dis-
placed by newly developing radiotherapy, which resulted 
in fast tumor destruction and pain relief, although not 
necessarily in complete tumor eradication, especially at 
the stage of advanced, metastatic disease.
With the progress of immunology it became clear that 
the mechanism of action of Coley’s toxin involves acti-
vation of the immune system and a multilevel modula-
tion of immune response. This understanding restored 
interest in possible therapeutic applicability of Coley’s 
approach. Richardson and coworkers (1999) compared 
the effectiveness of Coley’s toxin with contemporary 
cancer therapies based on published results concerning 
patients treated with Coley’s toxin and matched controls 
from National Cancer Institute’s Surveillance Epidemiol-
ogy End Result database (Richardson et al., 1999). They 
found higher rates of ten-year survival of Coley’s pa-
tients compared to patients subjected to modern treat-
ment in kidney cancer (33 vs. 23%), ovarian cancer (55 
vs. 29%), and sarcoma (50 vs. 38%), which gives food for 
thought. The attempts to re-evaluate Coley’s concept are 
undertaken anew. In 2012 the new phase 1 clinical trial 
investigating the safety and the dosage of biochemically 
well-defined and good manufacturing practice (GMP)–
compliant Coley’s toxin, presently known as MBV 
(mixed bacterial vaccine) was started in the Ludwig In-
stitute for Cancer Research. It involves patients suffering 
from cancers expressing NY-ESO-1 antigen, including 
metastatic melanoma, head and neck carcinoma, sarcoma 
and prostate cancer (Karbach et al., 2012). The results of 
the trial have not been published yet.
In line with Coley’s concept of using bacteria in can-
cer therapies, other bacterial species were evaluated 
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for a possible anti-tumor effect. Early experiments on 
“hemorrhagic allergy” in 1910s and 1920s showed that 
animals injected with bacterial filtrates developed hemor-
rhagic necrosis upon re-challenge with bacteria (so called 
Sanarelli-Shwartzman phenomenon). In particular, this 
condition was caused by Bacillus typhosus, which used to 
be a synonym for Salmonella Typhi at that time (Shwartz-
man, 1928). Interestingly, this shock syndrome induced 
a therapeutic effect in tumor-bearing animals (Shwartz-
man, 1935). However, the studies were discontinued due 
to very high treatment-related mortality; nowadays the 
adverse effects can be explained by strong stimulation 
of proinflammatory cytokines including tumor necrosis 
factor (TNF) by endotoxin and other bacterial products. 
Bacillus Calmette-Guerin (BCG), attenuated bovine tu-
berculosis bacteria (Mycobacterium bovis), has been used 
for decades as a vaccine protecting against tuberculosis. 
However, it also appeared to be one of the most suc-
cessful cancer immunotherapeutics. BCG, in the form 
of repeated intravesical instillations, has already been in 
use for over 30 years as a standard method to prevent 
cancer recurrence after endoscopic surgery of interme-
diate- and high-risk non-muscle invasive bladder cancer 
(Kawai et al., 2013). It is also effective against inoperable 
bladder carcinoma in situ resulting in a 70–75% complete 
response rate (Alexandroff et al., 1999). Unfortunately, in 
other tumor types BCG application has not proved to 
be more effective than conventional therapies (Alexan-
droff et al., 1999).
BAcTeRIAl cANceR TheRAPIeS cAN AddReSS The 
Key ISSueS IN cANceR TReATMeNT
Starting from 1946, chemotherapy gradually became 
the principal therapeutic strategy in cancer and bacterial 
therapies were largely forgotten. The success of small-
molecule drugs in cancer treatment was remarkable, but 
turned out to be incomplete. Chemotherapy of many 
tumors suffers from limited efficacy towards cancer 
cells and damaging action towards normal cells. Both 
phenomena have a significant impact on therapeutic 
outcomes, being responsible for incomplete tumor kill-
ing and adverse effects in other tissues. The two factors 
responsible for those clinical drawbacks are: low speci-
ficity towards cancer tissue and insufficient penetration 
of the tumor by chemotherapeutics. Cancer cells form 
a complex and heterogeneous system with areas of high 
metabolism, rich in nutrients and oxygen, as well as dis-
tal regions of poor perfusion, quiescence and necrosis 
(Saunders et al., 2012).
The use of bacteria as anticancer agents might have 
multiple advantages over other therapeutic approaches. 
Bacterial therapies can benefit from microbial metabo-
lism, motility and sensitivity to address a number of is-
sues related to currently used treatment modalities. One 
of the most important issues, relevant to virtually all 
chemotherapeutic and biological treatments, is limited 
accessibility of the tumor tissue to passively-distributed 
therapeutics. Both in the case of small molecule drugs, 
as well as larger molecules — cytokines, antibodies or 
even viruses — the therapeutic agent diffuses from the 
bloodstream into the periphery, with no transport system 
that could cross biological barriers, act against haemo-
dynamic gradients or facilitate preferential accumulation 
in the tumor tissue. In fact systemic delivery of passive 
therapeutics produces relatively large drug concentra-
tions in the bloodstream and relatively low drug concen-
trations in the tumor, resulting in limited efficacy and 
increased extratumoral toxicity. Bacteria offer unique 
mechanisms that can facilitate site-specific treatment, 
highly focused on the tumor and safe to other tissues. 
This can be possible due to several features of bacteria-
based therapeutics:
environmental sensing
Tumor tissue has a complex and heterogenic metabo-
lism that makes it particularly resistant to systemic treat-
ment. The natural ability of bacteria to receive signals 
via chemoreceptors can be used to effectively target this 
unique microenvironment. Oxygen concentration is one 
of the most important signals for anaerobic bacteria and 
is of particular interest in anticancer therapy since hy-
poxia is a common feature of tumors. Moreover, auxo-
trophic bacterial strains that rely on the uptake of certain 
metabolites can recognize the tumor microenvironment 
as a source of nutrients. This phenomenon can facili-
tate specific accumulation of bacteria in the tumor. One 
of the most effective examples is the use of Clostridium 
spores that can only germinate in oxygen-free tumor re-
gions (Dang et al., 2001).
Motility
The bacterial microorganism is not only capable of 
detecting chemoattractants, but can also actively follow 
chemical gradients. This contrasts with passive therapeu-
tics that simply diffuse into tissues from the circulation. 
Bacteria are able to penetrate deep into the tumor tis-
sue and perform specific actions, e.g. express proteins 
or transfer genes, to tumor cells localized remotely from 
the vasculature. This feature can also allow bacteria to 
cross physiological barriers and accumulate in cellular re-
gions that are either distant and inaccessible for passive 
therapeutics or quiescent and unresponsive to chemo-
therapy. For example, motile strains of Salmonella were 
shown to effectively penetrate tumor tissue in vitro (Toley 
& Forbes, 2012). However, the role of bacterial motil-
ity in in vivo tumor localization is unclear (Stritzker et al., 
2010).
Active delivery
Unlike chemical or biological molecules, microorgan-
isms are metabolically active and are able to perform 
specific metabolic tasks at the tumor site. These include 
the production of cytotoxic agents (e.g. bacterial toxin), 
expression of immunomodulatory molecules (e.g. cy-
tokine) or enzymatic conversion of a prodrug into an ac-
tive therapeutic. Strains derived from intracellular patho-
gens can infect tumor cells and deliver specific proteins 
or genes to the tumor tissue (St Jean et al., 2008). Nev-
ertheless, the intratumoral action is not always necessary 
as bacteria can also express tumor-related antigens to 
stimulate systemic anticancer immune responses. A Lis-
teria monocytogenes-based cancer treatment that has recently 
entered clinical development is an example of this ap-
proach, where the bacterium delivers tumor antigens di-
rectly to the antigen presenting cells (Singh & Wallecha, 
2011).
controlled propagation
Preferential growth in tumor tissue exhibited by many 
bacterial species is not exclusive to bacteria; experimental 
oncolytic viral therapies are based on a similar principle. 
However, once administered to the patient viral vectors 
are beyond external control. In contrast, bacterial thera-
peutics are susceptible to antibiotic treatment and there-
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fore fully manageable in the clinical setting – therapy 
can be stopped at the onset of adverse effects or when 
the bacteria are no longer needed. In fact the use of live 
biotherapeutics that contain antibiotic resistance genes 
in clinical trials is not recommended by the regulatory 
agencies1.
1Please refer to: Guidance for Industry: Early Clinical Trials with Live 
Biotherapeutic Products, US Food and Drug Administration, 2012; 
Environmental Risk Assessments for Medicinal Products containing, or 
consisting of, Genetically Modified Organisms, European Medicines 
Agency, 2007
Immunostimulation
Bacterial vectors augment the anti-tumor immune re-
sponse not only because of their cargo but also due to 
their own potent immunostimulatory activity. A growing 
tumor creates an immunosuppressive environment and 
establishes immune escape mechanisms that limit the 
maturation of dendritic cells (DCs) as well as the priming 
and migration of specific T cells into the tumor. Bacteria 
provide a strong danger signal to the immune system. 
The specific conserved bacterial structures such as com-
ponents of the cell wall or unmethylated CpG sites in 
bacterial DNA constitute so-called pathogen-associated 
    Table 1. overview of candidate live attenuated bacteria strains for cancer treatment.
Parental species/strain General features Research status
Mycobacterium bovis (BCG) Obligate aerobe, non-motile, 
gram-positive, facultatively 
intracellular, pathogenic to 
animals
Approved for bladder cancer management as intravesical BCG thera-
py, proven to be more effective than intravesical chemotherapy (revie-
wed by Kawai et al., 2013).
Salmonella Typhimurium ssp. Facultative anaerobe, motile, 
gram-negative, facultatively 
intracellular, broad-host 
pathogen
Transplantable and genetic animal tumor models in immunodeficient 
and immunocompetent mice.
Completed and ongoing phase 1 clinical trials in melanoma (S. Ty-
phimurium VP20009) (Toso et al., 2002) and liver cancer patients (S. 
Typhimurium x4550 expressing IL-2), respectively.
Salmonella Typhi ssp. Facultative anaerobe, motile, 
gram-negative, facultatively 
intracellular, human-adapted 
pathogen
Growth inhibition of subcutaneous LM3 mammary adenocarcinoma in 
BALB/c mice after S. Typhi CVD 915 multiple treatment (injection into 
the tumor, peritumoral tissue and draining lymph node areas) (Ven-
drell et al., 2011).
Ongoing phase 1 clinical trial with licensed oral S. Typhi Ty21a strain 
carrying VEGFR2 coding sequence under the control of eukaryotic pro-
moter for anti-angiogenic therapy and immunotherapy of pancreatic 
cancer (Niethammer et al., 2012).
Clostridium sp. spores Anaerobic, gram-positive, 
sporulating, vegetative 
forms are motile; pathoge-
nicity:
C. sporogenes — rarely,
C. novyi — yes,
C. beijerinckii — no
Strains modified to deliver pro-drug converting enzymes, cytokines, 
antibodies against tumor antigens. Spores administered systematically 
germinate and multiply only in hypoxic/necrotic areas of tumors cau-
sing significant oncolysis (reviewed by Umer et al., 2012)
Ongoing phase 1 clinical trial of C. novyi-NT spores in patients with 
solid tumor malignancies1.
Escherichia coli Nissle 1917 Facultative anaerobe, motile, 
gram-negative, non-patho-
genic probiotic strain for 
treatment of gastrointestinal 
disorders
Intravenous administration of bacteria expressing azurin (apoptosis 
inducing protein) decreased the number of lung metastases in ortho-
topic 4T1 breast cancer in BALB/c mice and restrained growth of sub-
cutaneous B16 melanoma in C57Bl/6 mice (Zhang et al., 2012b).
Escherichia coli K-12/LLO Strain expressing hly gene 
encoding modified listerioly-
sin (LLO) lacking its N-termi-
nal signal sequence
E. coli MC4100(DE3) modified with plasmid-encoded hly gene for 
truncated listeriolysin (LLO) in order to facilitate antigen export from 
phagosome to macrophage cytoplasm for antigen presentation in 
association with MHC class I. Strain co-expressing LLO and truncated 
WT1 (Wilms tumor gene 1) induced antitumor effect against WT1-
-expressing tumors in mice (RMA thymoma and MBL2 leukemia) thro-
ugh induction of CTLs and inhibition of Treg. Paraformaldehyde-fixed 
bacteria were administered in preventive and therapeutic setting (Dai 
et al., 2009).
Listeria monocytogenes Facultative anaerobe, motile, 
gram-positive, facultatively 
intracellular, pathogenic to 
animals and human, actively 
escape into cytosol of infec-
ted cell
Bacteria-mediated transfer of plasmid DNA into mammalian cells (bac-
tofection) (reviewed by Tangney et al., 2010).
Regression of established transplantable tumors and breaking im-
mune tolerance in genetic tumor models in mice administered with 
L. monocytogenes dal-, dat-, and actA-deleted strain secreting HPV-16 
E7 antigen associated with cervix, head and neck cancer; Her-2/neu 
breast cancer antigen or prostate specific antigen (PSA) (reviewed by 
Paterson et al., 2010).
L. monocytogenes HPV-16 E7 (ADXS11-001)  = ongoing phase 2 clinical 
trial for cervical cancer and phase 1 trial for HPV-16+ oropharyngeal 
carcinoma2.
Shigella flexneri Facultative anaerobe, non-
-motile, gram-negative, 
facultatively intracellular, 
human pathogen
Intravenous injection of S. flexneri M90T aroA mutant strain to mice 
bearing 4T1 subcutaneous tumors or to spontaneous breast cancer 
bearing transgenic MMTV-HER2 mice resulted in apoptosis and deple-
tion of tumor associated macrophages (TAMs), which correlated with 
pronounced 4T1 tumor growth inhibition (Galmbacher et al., 2010).
    1Please refer to the NCT01118819 clinical trial listed at ClinicalTrials.gov; 2Please refer to the ClinicalTrials.gov database and clinical trials 
     no. NCT01266460 and NCT01598792, respectively
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molecular patterns (PAMPs) that are recognized by Toll-
like receptors expressed by innate immune cells. PAMPs 
activate innate- and initiate adaptive immune responses. 
The induction of TNF, IFNg and IL-12 results in the 
recruitment and activation of DCs which upon migra-
tion to the lymph nodes may efficiently present tumor 
antigens to T cells (Chorobik & Marcinkiewicz, 2011). It 
has been shown that indeed microorganisms colonizing 
tumors and promoting an inflammatory reaction in the 
tumor microenvironment potentiate the anti-tumor host 
response (Avogadri et al., 2005).
The unique features of bacterial therapeutics create 
the opportunity for novel anticancer strategies, that com-
bine tumor-related molecular gradients, natural bacterial 
features and genetic engineering. Bacteria meet all the re-
quirements for an ideal tumor-targeting agent and might 
become a novel tool in the anticancer toolbox (Forbes, 
2010). A summary of the bacterial strains studied in can-
cer treatment is shown in Table 1.
Salmonella hAS A NuMBeR of feATuReS 
fAVoRABle foR cANceR TheRAPy
Salmonella belongs to the Enterobactericae family, a group 
of Gram-negative, facultatively anaerobic and facultative-
ly intracellular pathogenic bacteria. Currently, based on 
genome sequence similarity, the genus Salmonella is cat-
egorized into two species S. bongori and S. enterica which 
in turn is divided into six subspecies including S. enteri-
ca subsp. enterica (Tindall et al., 2005). According to the 
White-Kauffman-Le Minor scheme, the subspecies are 
classified into more than 2 500 serovars by serotyping: 
O-antigens (polysaccharide domain of the cell surface 
LPS); H1, H2 antigens (flagellin proteins) and the Vi 
antigen (Guibourdenche et al., 2010). New classification 
methods including genome-based techniques are current-
ly under development.
In humans, Salmonella enterica subsp. enterica serovars 
Typhimurium and Typhi are causative agents of gastro-
enteritis and typhoid fever, respectively. There are more 
than 27 million cases of typhoid fever worldwide each 
year with a mortality rate of 0.8% resulting from intes-
tinal perforation and peritonitis or severe toxic encepha-
lopathy connected with myocarditis and hemodynamic 
shock (Parry et al., 2002). Infections with S. enterica sero-
var Typhimurium result in an estimated 94 million cases 
of gastroenteritis worldwide and 0.16% mortality (Feasey 
et al., 2012). S. Typhi is an exclusively human pathogen, 
while hosts of S. Typhimurium include rodents, poultry 
and cattle.
Salmonella Typhimurium and Salmonella Typhi are 
closely related serotypes of S. enterica species which 
differ in host adaptation and the outcome of infec-
tion. Depending on the serotype and host, Salmonella 
colonizes solely the intestinal epithelium leading to 
gastroenteritis or spreads beyond the gut mainly to 
liver and spleen causing typhoid fever. S. Typhimu-
rium infection in humans is restricted to the digestive 
tract, with the exception of infants, elderly or immu-
nocompromised individuals in whom it can spread, 
while in mice S. Typhimurium causes enteric fever. 
On the contrary, S. Typhi causes typhoid fever in 
humans but is not pathogenic to animals. In general, 
serotypes that lack host specificity, such as S. Typh-
imurium, are more frequently associated with disease 
in young rather than in adult animals, suggesting their 
non-optimal adaptation to mature immune system 
(Baumler et al., 1998).
About 90% of the genes in S. Typhi and S. Typhimu-
rium serovars are identical (McClelland et al., 2001), but 
among about 4 000 genes of S. Typhi, more than 200 
are functionally disrupted or inactive, while most of their 
homologs are still fully functional in S. Typhimurium. 
Genes that differ include virulence factors that deter-
mine the pathogenic potential, which can in part explain 
the restricted host range of S. Typhi (McClelland et al., 
2001). The majority of virulence factors are encoded by 
genes grouped in a few clusters in the genome, termed 
Salmonella Pathogenicity Islands (SPIs). S. Typhimurium 
and S. Typhi genomes share 11 SPIs, one is specific for 
S. Typhimurium (SPI14) and four are specific for S. Ty-
phi (SPI7, 15, 17 and 18) (Kolyva, Waxin, and Popoff, 
1992).
Salmonella sp. has an ability to multiply inside phago-
cytic and nonphagocytic cells including macrophages, 
dendritic cells (DCs), neutrophils, M cells and epithelial 
cells (Malik-Kale et al., 2011). The ability of Salmonella to 
invade and survive within a host cell is dependent on 
two Type III Secretion Systems (T3SS), the multiprotein 
complexes with a needle-like structure present on the 
bacteria cell wall. Proteins involved in the assembly of 
the two major T3SSs of Salmonella are encoded by SPI1 
and SPI2. T3SS1, encoded by SPI1, is required for ef-
ficient invasion of nonphagocytic cells. In contrast, the 
expression of SPI2-encoded T3SS2 is induced follow-
ing the internalization of Salmonella into host cells and is 
required for post-invasion processes (Velge et al., 2012). 
During the invasion, some SPI1 encoded proteins such 
as InvG, InvJ, PrgH, PrgI, PrgK and SpaO are respon-
sible for the assembly of the needle complex, whereas 
others, including SipB, SipC and SipD, translocate the 
effector proteins through this needle. Regulation of gene 
expression in response to the surrounding microenviron-
ment depends on several two-component systems, such 
as PhoQ/PhoP whose expression is induced by Mg2+ 
starvation and low pH (Lucas et al., 2000). Another sys-
tem, OmpR-EnvZ, responds to changes in osmolarity 
and regulates invasion (Bajaj et al., 1995) as well as in-
tracellular survival. Upon internalization, Salmonella modi-
fies the phagosome into a Salmonella-Containing Vacuole 
(SCV), which is characterized by the presence of some 
lysosomal membrane proteins, low pH, and transient in-
teractions with the endocytic pathways. At early stages 
of maturation, SCV recruits and quickly looses early en-
docytic markers, such as the early endosomal antigen 1 
(EEA-1) or transferrin receptor (TfR) (Steele-Mortimer 
et al., 1999). At later points of maturation it acquires sev-
eral late endosomal markers, including LAMP1 (Lysoso-
mal-Associated Membrane Protein 1) (Steele-Mortimer, 
2008). Bacterial replication is accompanied by the for-
mation of dynamic membrane tubules termed Salmonella-
Induced Filaments, which extend from SCV throughout 
the cell (Schroeder et al., 2011). The maturation of SCV 
is controlled by SPI2-encoded effectors which allow 
bacteria to avoid phagosome-lysosome fusion and deg-
radation and protect them against reactive oxygen and 
nitrogen species (Chakravortty et al., 2002; Janssen et al., 
2003).
After the ingestion of S. enterica, the bacteria use dif-
ferent routes to cross the intestinal barrier. The main 
route leads through the receptor-mediated endocytosis 
by microfold cells (M-cells) in Peyer’s patches (Jepson & 
Clark, 2001), independently of SPI1 and SPI2 (Martinez-
Argudo & Jepson, 2008). Then the bacteria are taken up 
by the underlying macrophages. Enterocytes of the intes-
tinal epithelium, except for the M cells, engulf Salmonella 
by macropinocytosis in a SPI1-dependent manner. The 
Vol. 60       289Salmonella and cancer: from pathogens to therapeutics
bacteria can be also engulfed by DCs (Swart & Hensel, 
2012). In epithelial cells S. Typhimurium can reside and 
replicate in SCV, as well as in the cytosol (Malik-Kale 
et al., 2012); however, these two intracellular populations 
of bacteria are transcriptionally distinct: the intravacuolar 
bacteria are SPI2-induced, while the cytosolic bacteria 
are SPI1-induced and flagellated (Knodler et al., 2010). 
Salmonella induces caspase-1 and -2 mediated apoptosis 
of infected macrophages and epithelial cells (Jesenberger 
et al., 2000; Kim et al., 1998; Monack et al., 1996). Ap-
optosis depends mainly upon the SPI1 effector protein, 
SipB, delivered to the host cell by SPI1-encoded T3SS 
(Jesenberger et al., 2000). Bacteria, engulfed by mac-
rophages and DCs spread from Peyer’s patches to mes-
enteric lymph nodes, spleen and liver. The ability of Sal-
monella to elicit systemic disease is serovar-dependent and 
correlates with its capability to survive and replicate in-
side the host cell and to avoid the host adaptive immune 
response (reviewed by Swart & Hensel, 2012).
TheRAPeuTIc Salmonella STRAINS ARe deRIVed 
fRoM S. TyPhIMuRIuM oR S. TyPhI
S. Typhimurium infection in mice remains the domi-
nant animal model of typhoid fever because it leads to 
comparable systemic disease with dissemination of bac-
teria to the lymphatic system and peripheral organs. 
Hence the prevalence of S. Typhimurium-based tumor 
therapeutic vectors studied in murine models of cancer. 
The choice of S. Typhimurium over S. Typhi for pre-
clinical research on cancer therapy could be arguable but 
is legitimated by the availability of suitable animal mod-
els. Some improvement was made by the development 
of a transgenic mouse model of S. Typhi infection (Song 
et al., 2010), but it has not been applied to Salmonella-
based tumor therapy studies yet. Nevertheless, a superior 
induction of immune response to heterologous antigen 
delivered by an orally administered vaccine strain of S. 
Typhimurium over S. Typhi was shown in a clinical trial 
(Angelakopoulos & Hohmann, 2000). Both serotypes 
are amenable to genetic modifications of virulence and 
in terms of safety are equally eligible as live attenuated 
therapeutic strains. There has already been some suc-
cess in the clinical use of attenuated Salmonella strains. 
S. Typhimurium VNP20009 was shown to be safe when 
administered to cancer patients (Toso et al., 2002) and 
S. Typhi Ty21a, a live attenuated oral vaccine against ty-
phoid fever, has already been applied for more than 30 
years to adults and children above 6 years of age who 
are at risk of S. Typhi exposure. A phase I clinical trial 
evaluating the safety, tolerability, and effects of the S. 
Typhi Ty21a strain used as a DNA delivery vehicle in 
cancer patients has been announced (Niethammer et al., 
2012) but its results are not yet available.
Attenuation of virulence is crucial for the develop-
ment of new Salmonella-based vector strains in order to 
elicit an appropriate profile of the immune response. 
Up to date about 50 genes of Salmonella spp. have been 
proven to be feasible for inactivation in order to obtain 
an attenuated derivative with modified virulence or met-
abolic functions. Gene inactivation is achieved by labo-
ratory selection of the desired phenotype, for example 
by passaging bacteria through selective conditions and 
screening for survivors, or is the result of site-directed- 
or chemical mutagenesis. Inactivation of genes coding 
for proteins involved in metabolic pathways generates 
auxotrophic strains, i.e. dependent on external sources 
of nutrients, for example aromatic amino acids (aro mu-
tants) or purines (pur mutants). Direct attenuation of vir-
ulence involves inactivation of genes encoding proteins 
interacting with the infected organism or factors regu-
lating their expression. The latter include: (i) phoP and/
or phoQ, which regulate expression of many genes, e.g. 
those contributing to the resistance against antimicrobial 
peptides and genes located in pathogenicity islands, (ii) 
cya and crp genes coding for global regulatory factors in-
volved in expression of many proteins of cellular catabo-
lism, (iii) htrF gene, which enables survival under stress 
conditions (Garmory et al., 2002; Raupach & Kaufmann, 
2001; Raupach et al., 2003). The attenuating mutations 
introduced into Salmonella experimental strains are sum-
marized in Table 2.
An interesting example comes from a sophisticated 
work of Robert Hoffman’s group: A1-R is an auxo-
trophic Salmonella strain developed for increased tu-
mor targeting and limited toxicity. First, the research-
ers obtained an A1 auxotrophic strain dependent on 
an external source of leucine and arginine by nitro-
soguanidine (NTG) mutagenesis of S. Typhimurium 
14028-GFP. To further enhance tumor targeting of 
S. Typhimurium A1, bacteria were injected i.v. into 
nude mice bearing HT-29 human colon adenocarci-
noma. GFP-expressing bacteria isolated from the ex-
cised infected tumors, were termed A1-R and had an 
increased ability to adhere to cancer cells; the number 
of A1-R bacteria attached to HT-29 cells in vitro was 
approximately six times higher than that of the paren-
tal A1 strain (Zhao et al., 2006).
S. Typhimurium A1-R was tested in numerous human 
tumor xenografts in nude mice, such as MARY-X breast 
tumor (Zhao et al., 2006), orthotopic prostate PC-3 can-
cer (Zhao et al., 2007), orthotopic human pancreatic can-
cer (Nagakura et al., 2009), orthotopic U87 spinal cord 
glioma (Kimura et al., 2010), orthotopic MDA-MB-435 
breast cancer (Zhang et al., 2012a), lung fibrosarcoma 
(Hayashi et al., 2009b) and lung osteosarcoma (Hayashi et 
al., 2009a) resulting in a significant tumor growth inhibi-
tion in all tested models, with complete tumor regression 
in a few of them.
Applicability of A1-R in metastatic disease has also 
been tested. Hayashi et al. (2009b) developed a lymph 
node metastasis model of human pancreatic cancer 
(XPA-1) by injecting XPA-1 cells into the inguinal lymph 
node of nude mice which resulted in tumor growth 
in the axillary lymph node. Five of six mice had their 
lymph node metastases eradicated within 7–21 days after 
intravenous treatment with A1-R in contrast to growing 
metastases in the untreated control group (Hayashi et al., 
2009b).
A1-R has also been tested in immunocompetent mice 
bearing murine Lewis lung carcinoma (Tome et al., 2013). 
The authors proposed to apply a priming dose of 1×106 
cfu followed, 4 hours later, by a therapeutic dose of 
1×107 cfu of A1-R. The priming dose resulted in an el-
evated serum level of TNF and tumor vessel destruction, 
which could facilitate the invasion of tumor by bacteria.
As it can be expected, the mode of attenuation affects 
the quality of the anti-Salmonella immune response. While 
cytokines of the Th1 type (IFNγ, IL-12, IL-18) are cru-
cial for protection against Salmonella in mice and humans, 
different mutant Salmonella strains require alternative cy-
tokines for the control of infection. Studies with knock-
out mice showed that IFNγ and TNF were essential for 
the early control of infection with both wild type and 
aroA mutant strains. In contrast, TNF was not required 
for the clearance of the aroA mutant (Raupach & Kauf-
mann, 2001).
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Attenuated Salmonella strains preferentially colonize 
solid tumors and inhibit their growth in animal models 
(Bermudes et al., 2002; Pawelek et al., 1997; Zhao et al., 
2005). In some therapeutic approaches attenuated strains 
were used without any further modifications to exert 
tumor-directed cytotoxic effects and induce proper anti-
tumor immune response. Apart from the A1-R strain de-
scribed above also the application of the S. Typhimurium 
Χ9241 strain brought successful results. Bacteria injected 
intratumorally to CT26 tumors or CT26 tumors express-
ing human tumor antigen, Her-2/neu, significantly inhib-
ited tumor growth. Surprisingly, they did not potentiate 
tumor-antigen-specific cellular immunity. However, they 
induced an important functional shift in the phenotype 
of tumor-infiltrating CD11b+Gr-1+ subpopulation of 
leukocytes (myeloid derived suppressor cells, MDSC) to-
wards immunogenic TNF-secreting neutrophils. Moreo-
ver, the therapy reduced the percentage of regulatory T 
cells which may promote tumor development (Hong et 
al., 2013).
Thanks to the intracellular lifestyle and immunomodu-
latory properties attenuated Salmonella strains are also 
used as vectors for the delivery of therapeutic molecules. 
The cargo is a genetic material which codes for proteins 
including tumor antigens (described in the next chapter), 
cytokines, apoptosis-inducing factors, prodrug-converting 
enzymes, or short hairpin RNAs (shRNAs) able to si-
lence expression of a protein of choice. Numerous ap-
proaches were developed to enhance and navigate the 
immunomodulatory properties of Salmonella through ge-
netic modifications that ensure the delivery of proapop-
totic molecules or cytokines straight to the tumor, which 
limits their potential undesired systemic side effects. The 
examples are listed in Table 3.
The group of John C. Reed demonstrated a significant 
increase in tumor growth inhibition by a Salmonella strain 
expressing IL-18 in immunocompetent mice (Loeffler 
et al., 2008). The modified and parental strains showed 
comparable toxicity limited to the spleen and liver. IL-18 
stimulates T cell and NK cell to proliferation, cytotoxic-
ity and cytokine production. Administration of IL-18-se-
creting Salmonella did not improve tumor infiltration by 
CD8+ T lymphocytes but led to increased infiltration by 
granulocytes, CD4+ T cells and DX5+ NK cells, when 
compared to Salmonella control strain (Loeffler et al., 
2008).
In order to enhance the proapoptotic activity of S. Ty-
phimurium towards infected cancer cells several research 
groups took an advantage of apoptosis-inducing factors 
and equipped bacteria with appropriate expression vec-
tors. TRAIL (TNF-related apoptosis-inducing ligand) 
has a capacity to selectively induce apoptosis in a wide 
variety of cancer cells but hardly in normal cells which 
makes it a promising cancer therapeutic (Hylander et al., 
2005; Shanker et al., 2008; Walczak et al., 1999; Yagita 
et al., 2004). Similarly to TNF, TRAIL exerts its proa-
poptotic effect through the death receptor-dependent 
pathway which activates the caspase cascade (LeBlanc & 
Ashkenazi, 2003).
Ganai et al. (2009) constructed an expression vector 
placing TRAIL under the promoter of recA gene in-
volved in the prokaryotic SOS response to DNA dam-
age (Anderson & Kowalczykowski, 1998). It created a 
radiation-inducible system, where expression of TRAIL 
was turned on by genotoxic damage evoked by radiation. 
Such a system enables temporal and spatial control of 
the gene expression, additionally increasing the selectivity 
of the therapy towards cancer cells subjected to radio-
therapy. Intravenous administration of S. Typhimurium 
VNP20009 equipped with a PrecA-TRAIL construct 
(VNP/pRE-TR) into Balb/c mice bearing subcutaneous 
4T1 mammary carcinoma followed by 2 Gy whole body 
Table 2. Attenuated strains of S. Typhimurium developed as bacterial vaccine vectors.
Parental strain Modified strain Attenuation mode
ATCC 14028 A1-R leucine and arginine auxotrophs (Zhao et al., 2005)
SL1344 BRD509 aroA aroD
aromatic compound dependent (Strugnell et al., 1992)
NCTC12023
(ATCC 14028)
MvP728 purD htrA
adenine dependent; defective intra-macrophage survival (Xiong et al., 2010)
Not stated Re88 aroA dam (Xiang et al., 2001)
DNA adenine methylase mutants are defective in protein secretion, cell invasion 
and M cell cytotoxicity
SL3261 SB824 aroA sptP (encodes virulence protein SptP) (Panthel et al., 2005)
14028s SHJ2037 relA spoT (genes that encode ribosome-bound and cytosolic ppGpp synthetase, 
respectively)
accumulates in infarcted myocardium due to defective ppGpp synthesis (ΔppGpp) 
(Song et al., 2010)
SL1346 SL3261 aroA (Meng et al., 2010)
2337–65 (WRAY) SL7207 aroA
dependent on p-aminobenzoate and 2,3-dihydroxybenzoate for the synthesis of 
aromatic amino acids; these two compounds are not available in a mammalian 
host (Hoiseth & Stocker, 1985)
ATCC 14028 VNP20009 (YS1646) msbB purI
purine dependent; reduced ability to induce septic shock due to altered lipid A 
structure (Low et al., 2004)
SL7207 YB1 aroA
modified to express asd essential gene under hypoxia-induced promoter (Yu et al., 
2012)
UK-1 X4550 cya crp asd (Saltzman et al., 1996)
adenylate cyclase and cyclic AMP receptor protein mutants are avirulent in mice
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γ-irradiation 2 days later resulted in a significant decrease 
in tumor growth. The combined treatment increased the 
tumor size doubling time by 50% compared to VNP/
pRA-TR treatment alone and by 100% in comparison 
to PBS control. The combined therapy has a synergis-
tic effect since irradiation alone barely influenced tumor 
growth (Ganai et al., 2009).
A similar approach was exploited by Chen et al. (Chen 
et al., 2012) who placed TRAIL cDNA under the control 
of nirB promoter induced by hypoxic conditions (Chat-
field et al., 1992). The S. Typhimurium VNP20009 strain 
carrying TRAIL expression vector was intraperitoneally 
administered to B16F10 melanoma-bearing C57BL/6 
mice. Significant inhibition of melanoma tumor growth 
Table 3. Therapeutic approaches based on S. Typhimurium modified to deliver apoptosis inducing or immune modulatory factors.
Vector Cargo Mouse strain Therapeutic scheme Outcome
BRD509 cDNA for TNF fu-
sed to 160 amino 
acid residue-N-
-terminal fragment 
of SipB under the 
control of bacterial 
lac promoter
C57Bl/6 s.c. TC-1 cervical 
tumor, B16F10 
melanoma
Two s.c. injections of 108 
CFU/mouse 7 and 14 days 
after s.c. inoculation of 
105 B16F10
Complete inhibition of 
tumor cell growth in 90% 
of animals, but these mice 
were not protected against 
second B16F10 challenge. 
Reduced growth of all listed 
tumors, although with diver-
se efficacy (Yoon et al., 2011)
BALB/c s.c. 4T-1 breast 
cancer, CT26 co-
lon cancer, and 
RENCA kidney 
carcinoma
SL7207 TRAIL and apoptin 
genes under the 
control of eukary-
otic promoters
BALB/c nude s.c. SGC-7901 
human gastric 
cancer (5 × 105 
cells)
Intratumoral injection 7 
days after tumor implan-
tation, repeated every 7 
days (2 × 106 CFU)
Cancer cell apoptosis in 
tumor tissue and tumor 
regression (Cao et al., 2010)
VNP20009 
and MVP728
Stat3 shRNA and 
survivin expressing 
plasmid
C57Bl/6 s.c. B16F10 me-
lanoma
(105 cells)
YS1646 with Stat3 shRNA 
i.v. injected at 107 CFU 
when tumor volumes 
were 50 mm3 or above 
(7–8 mm diameter), fol-
lowed by oral gavage 
with 107 CFU of MVP728 
with survivin expression 
plasmid
Enhancement of CD4+ and 
CD8+ T lymphocytes infil-
tration into tumors, incre-
ased tumor cell apoptosis, 
suppression of s.c. B16F10 
melanoma growth (Manuel 
et al., 2011)
VNP20009 cDNA for IL-18 
fused to N-terminal 
leader sequence 
for directing se-
cretion, under the 
control of bacterial 
ompC promoter
BALB/c s.c. CT26 colon 
carcinoma (105 
cells)
i.v. injection of 5 × 106 
CFU when tumors were 
visible (14 days after ino-
culation)
Reduced tumor growth, 
leukocyte infiltration into 
tumors, increased intra-
tumoral level of IL-1β, TNF, 
IFNγ
BALB/c s.c. D2F2 breast 
carcinoma (2.5 
× 105 cells)
i.v. injection of 5 × 106 
CFU on day 9, 14 and 19 
after tumor inoculation
Significant tumor growth 
inhibition
C57Bl/6 i.v. Lewis lung 
carcinoma (5 × 
104 cells)
i.v. injection 6, 13, and 
20 days after tumor cells 
injection
Reduced tumor burden in 
lungs (Loeffler et al., 2008)
VNP20009 IDO shRNA (immu-
nosuppressive mo-
lecule indoleamine
2,3 dioxygenase 1)
C57Bl/6 s.c. B16F10 me-
lanoma (2.5 × 
105 cells)
2.5 × 106 CFU injected 
intravenously twice, 4 
days apart, into mice with 
tumor diameters equal or 
greater than 7 mm
Synergistic effect of IDO 
silencing and S.
Typhimurium on tumor 
growth suppression. Incre-
ased tumor influx of
PMNs and intratumoral 
cell death. Tumor growth 
suppression occurred also 
in the absence of functional 
adaptive immunity (Blache 
et al., 2012)
VNP20009 TRAIL under the 
control of bacterial 
anaerobic-inducible 
nirB promoter
C57Bl/6 s.c. B16F10 me-
lanoma (5 × 105 
cells) and RM-1 
prostate cancer 
(2 × 105 cells)
i.p. injection of 105 CFU 
per mouse on day 7 for 
B16F10 or day 9 for RM-1 
after tumor inoculation
Increased levels of TRAIL in 
B16F10 tumor but not in 
liver or spleen and tumor 
growth inhibition. VNP-TRAIL 
was not more effective in 
tumor growth suppression 
of TRAIL-resistant RM-1 tu-
mors than VNP control strain 
(Chen et al., 2012)
VNP20009 CCL21 under the 
control of bacterial 
ompC promoter
BALB/c s.c. CT26 colon 
carcinoma (2.5 
× 105 cells)
Intravenous injection 9, 
14 and 19 days after tu-
mor inoculation
Significantly inhibited 
growth of subcutaneous tu-
mors and pulmonary tumor 
foci (Loeffler et al., 2009)
i.v. D2F2 breast 
carcinoma (5 
× 104 cells) for 
pulmonary tu-
mor model
i.v. injection of 5 × 106 
CFU at day 6, 13, and 20 
after tumor cells injection
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and extended survival time were observed. The TUNEL 
assay showed that the therapeutic effect of modified 
bacteria was associated with a significant increase in ap-
optosis of melanoma cells compared to mice receiving 
the control strain. Importantly, the immunohistochemical 
study revealed that indeed TRAIL was preferentially ex-
pressed in the hypoxic, necrotic area of the tumor, and 
not in the oxygenated liver or spleen, which may explain 
limited toxicity of TRAIL in normal tissues.
It has been shown that Smac (second mitochondria-
derived activator of caspases) is involved in TRAIL-in-
duced apoptosis and may affect the efficiency of TRAIL-
based therapies (Deng et al., 2002; Zhang et al., 2001). 
Also in vivo studies showed that complete regression of 
established glioma in a mouse model was achieved only 
when TRAIL therapy was associated with Smac adminis-
tration (Fulda et al., 2002; Pei et al., 2004). Fu et al. (2008) 
took an advantage of this observation and engineered a 
modified S. Typhimurium SL3261 strain carrying a du-
al-gene vector coding for both Smac and TRAIL. The 
cDNAs were placed under the promoter of human tel-
omerase reverse transcriptase, highly active in majority 
of cancers and generally inactive in normal differenti-
ated cells (Kim et al., 1998). LL/2 Lewis lung carcinoma, 
B16F10 melanoma and 4T1 mammary carcinoma cells 
infected with the modified bacteria showed high expres-
sion levels of both proteins accompanied by a high rate 
of apoptosis. Moreover, oral administration of the modi-
fied strain significantly suppressed tumor growth in all 
tested mice models (LL/2, B16F10, 4T1), without any 
observable side-effects. The volumes of the tumors were 
lowered approximately by 65–75% compared to groups 
treated with a control strain and by 90% compared to 
PBS-treated animals.
Cao et al. (2010) applied combination of TRAIL with 
another apoptosis-inducing factor — apoptin (VP3), a 
protein of the chicken anemia virus proved to promote 
tumor cell-specific apoptosis in a p53-independent man-
ner (Zhuang et al., 1995). The study showed that intratu-
moral administration of S. Typhimurium SL7207 carrying 
apoptin and TRAIL coding sequences under the control 
of eukaryotic cytomegalovirus immediate early promoter 
to human gastric tumor xenografts in nude mice result-
ed in increased effectiveness of bacteria-mediated tumor 
growth suppression, with complete tumor regression in 
some animals. TUNEL assays in tissue sections showed 
a higher apoptotic rate in mice treated with S. Typhimu-
rium SL7207 carrying apoptin and TRAIL genes com-
pared to a control strain (Cao et al., 2010).
Salmonella cAN Be AlSo uSed AS A TuMoR 
VAccINe VecToR
The vast majority of tumors express proteins or oth-
er antigens that are absent (or present only in very low 
quantities) in healthy adult tissues. These tumor-associ-
ated antigens (TAAs) are potentially immunogenic and 
tumor development is usually accompanied by specific, 
although often ineffective, anti-TAA immune response. 
TAA vaccines used for cancer therapy often fail, prob-
ably due to inadequate antigen presentation and insuffi-
cient activation of innate immunity. The application of 
Salmonella as a vector for TAAs should result in over-
coming both impediments. The first attempts to deliver 
TAA via Salmonella were undertaken in late 1990s. From 
that time numerous studies utilizing natural (mPSCA, 
mAFP, survivin, endoglin) or artificial (β-galactosidase) 
tumor antigens have proved that placing a TAA-coding 
transgene under strong cytomegalovirus promoter in 
a plasmid carried by Salmonella allows for TAA expres-
sion in the cytoplasm of infected cells or dendritic cells 
which engulfed the infected, apoptotic cells (Paglia et al., 
1998; Yrlid & Wick, 2000); TAA expression elicits ef-
ficient cell-mediated or both cell-mediated and humoral 
immune responses (Ahmad et al., 2011; Chou et al., 2006; 
Fest et al., 2009; Huebener et al., 2008; Jarosz et al., 2013; 
Paglia et al., 1998). However, this is not always the case. 
The group of Dai-Ming Fan transformed Salmonella with 
a plasmid, which expressed a fusion protein consisting 
of a mimotope of the gastric tumor antigen, MG2 with 
either PADRE T helper epitope (Guo et al., 2003) or 
HBcAg, a strong Hepatitis B virus T-cell-dependent and 
T-cell-independent antigen (Meng et al., 2005). Although 
oral administration of either Salmonella strain resulted in 
a partial inhibition of the growth of the subsequently in-
jected Ehrlich ascites carcinoma, only the humoral but 
not the cell-mediated response against MG2 could be 
detected (Guo et al., 2003; Meng et al., 2005).
It is believed that intracellular location of Salmonella 
within phagosomes may limit the ability to generate a 
MHC class I-restricted immune response towards trans-
gene-encoded proteins. However, Salmonella expresses a 
multi-protein complex, T3SS, to deliver some bacterial 
effector proteins into the host cell in order to modulate 
its functions and create a microenvironment favorable 
for bacterial survival and proliferation (Galan and Col-
lmer, 1999). A special N-terminal signal sequence directs 
bacterial proteins for export through T3SS to the host 
cell cytoplasm. This very mechanism was employed by 
several research groups to deliver Salmonella plasmid-
encoded tumor antigens to the host cell cytoplasm and 
thus make them available for the MHC class I presen-
tation. Instead of sequences encoding TAAs alone, the 
constructs coding for chimeric proteins consisting of a 
tumor antigen preceded by an N-terminal fragment of 
a bacterial protein subjected to T3SS export (contain-
ing secretion and translocation signals) were placed in 
the Salmonella plasmid. These included peptides derived 
from the SopE, SseF and YopE proteins (Jellbauer et al., 
2012; Manuel et al., 2011; Nishikawa et al., 2006; Zhu et 
al., 2010). The chimeric transgenes were usually placed 
under bacterial promoters activated after invasion of the 
host cell.
This approach was applied by Nishikawa et al. in an 
attempt to generate a therapeutic vaccine against cancers 
overexpressing the NY-ESO-1 antigen (Nishikawa et al., 
2006). This germ cell antigen seems to be a proper tar-
get for immunotherapy, since it is expressed by a broad 
variety of tumors but not by normal somatic cells. Fol-
lowing oral administration of the Salmonella-based vac-
cine that delivered NY-ESO-1 and assured its cytoplas-
mic localization, CD8+ T cell-dependent regression of 
established NY-ESO-1-expressing tumors was observed. 
What is more, the vaccine was able to initiate a process 
known as epitope spreading and was therefore effective 
even towards tumors lacking the NY-ESO-1 antigen. 
Intratumoral injection of this Salmonella strain delivering 
the antigen and engaging pre-existing NY-ESO-1-specific 
CD8+ T cells resulted in tumor regression and activation 
of subsets of T cells recognizing at least two different 
tumor antigens that were not delivered by Salmonella (Ni-
shikawa et al., 2006).
A more complex transgene was introduced into a 
Salmonella plasmid by Zhu et al., who worked on an ef-
ficient anti-melanoma vaccine (Zhu et al., 2010). It en-
coded a fusion protein consisting of the secretion and 
translocation signals of SopE and a fragment of the 
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melanoma-specific TRP2 (tyrosinase-related protein 2) 
antigen containing three immunodominant epitopes. The 
presence of Hsp70, often referred to as immunochaper-
one, facilitates the proper presentation of antigenic pep-
tides to cytotoxic T cells and may therefore enhance the 
anti-melanoma immune response. This vaccine induced 
a specific CTL response against B16F10 melanoma and 
showed strong protective as well as therapeutic effects 
(Zhu et al., 2010).
Another modification aiming in augmenting the pre-
sentation of Salmonella-delivered neuroblastoma antigens 
was proposed by the group of Lode (Fest et al., 2009; 
Huebener et al., 2008). The chimeric protein encoded by 
Salmonella plasmid contained a stably ubiquitinated tu-
mor antigen, either tyrosine hydroxylase- (Huebener et 
al., 2008) or survivin (Fest et al., 2009) fragments. The 
presence of ubiquitin guaranteed proteasomal degrada-
tion of proteins encoded by the transgenes and increased 
MHC I-mediated peptides presentation. This approach 
led to significant CD8+ T cell-dependent inhibition of 
neuroblastoma growth (Fest et al., 2009; Huebener et al., 
2008) and decreased the rate of metastasis (Huebener et 
al., 2008) or tumor growth upon rechallenge (Fest et al., 
2009).
Manuel et al. also chose survivin as an excellent tar-
get for tumor therapy (Manuel et al., 2011). This anti-
apoptotic protein is expressed at a low level in normal 
adult tissues but is abundant in essentially all solid tu-
mors (Altieri, 2003), as well as in endothelial cells during 
angiogenesis (Tran et al., 1999). However, unlike their 
predecessors, the researchers utilized bacterial promoter 
to express a codon-optimized transgene in Salmonella and 
used the SseF secretion signal to transport survivin to 
the cytoplasm of the infected cells. The combined ther-
apy consisting of sequential intravenous injection of two 
Salmonella strains: the first encoding shRNA targeting a 
tolerogenic transcription factor, and the second coding 
for SseF-survivin, turned out to be effective even in the 
case of large, well-established melanoma tumors. The si-
lencing of STAT3 expression, crucial for this very prom-
ising result, led to increased proliferation of intratumoral 
CD4+ and CD8+ T cells and elevated levels of granzyme 
B (Manuel et al., 2011).
Not only survivin but also other proteins overpro-
duced in endothelium during angiogenesis, such as 
VEGFR2, one of the VEGF receptors, or endoglin, a 
component of the TGFβ (Transforming Growth Factor 
beta) receptor complex, have been chosen as targets for 
Salmonella-based vaccines (Jarosz et al., 2013; Jellbauer et 
al., 2012). The induction of the CTL response against 
these antigens should reduce angiogenesis and destroy 
tumor vasculature leading to inhibition of tumor devel-
opment. Indeed, Salmonella carrying a plasmid encoding a 
fusion protein comprising the YopE secretion sequence 
and the fragment of VEGFR2 containing the CD8+ T-
cell epitope efficiently limited the growth of B16F10 
melanoma in both prophylactic and therapeutic settings 
(Jellbauer et al., 2012). The authors hypothesized that the 
vaccine may also affect the immunosuppresive tumor 
microenvironment by destroying the VEGFR2-positive 
subset of Treg lymphocytes.
Similarly, a combined therapy using orally applied Sal-
monella carrying endoglin cDNA with an intratumorally 
injected plasmid coding for interleukin-12 reduced mi-
crovessel density and diminished the number of Tregs 
within B16F10 tumors resulting in inhibition of the tu-
mor growth and prolonged survival of mice (Jarosz et al., 
2013).
Some examples of in vivo studies on the efficacy of 
various Salmonella Typhimurium-based anti-cancer vac-
cines are presented in Table 4.
Recently, a phase 1 clinical trial evaluating the safety 
of the first Salmonella Typhi-based oral vaccine coding 
for the full length human VEGFR2 and aimed at elicit-
ing an anti-VEGFR2 immune response has started and 
involves patients suffering from pancreatic cancer. The 
results of this trial are not yet available (Niethammer et 
al., 2012).
clINIcAl STudIeS INdIcATe TuMoR TARgeTINg 
AS The MAjoR lIMITATIoN of Salmonella-BASed 
TheRAPIeS
The mouse is a natural host for Salmonella enterica se-
rovar Typhimurium and this species is considered to be 
the most sensitive to VNP20009 infections. However, 
the maximum tolerated dose (MTD) of VNP20009 in 
mice is large and was estimated to be 0.5 × 108 colony 
forming units per kg of body weight, which makes this 
attenuated strain at least 50 000 times less virulent than 
the parental Salmonella (Lee et al., 2000). Importantly, 
similar values of MTD were estimated for other spe-
cies — dogs, pigs and monkeys (3.0 × 107, 1.9 × 108 and 
2.5 × 108 cfu/kg, respectively). Most of the adverse ef-
fects observed were transient and related to physiologi-
cal responses to infection and stress, rather than to the 
intrinsic toxicity of the bacterial treatment. The studies 
in pigs found no endotoxic or septic shock reactions. In 
tumor-bearing mice, VNP20009 accumulates preferen-
tially in tumors over livers at a ratio of 1000:1, but also 
in dogs with spontaneous neoplasia tumor colonization 
was detectable in 10 out of 24 Salmonella-treated cases 
(42%) (Thamm et al., 2005). Those promising features of 
preferential localization and apparent lack of toxicity al-
lowed VNP20009 to enter clinical development in 1999.
In the first-in-man study performed by Vion Pharma-
ceuticals Inc., a total of 25 patients — 24 with metastatic 
melanoma and one with metastatic renal cancer — were 
treated with 30-minute intravenous bolus infusions of 
VNP20009 dose ranging from 106 to 109 cfu/m2. On the 
basis of dose-limiting toxicity symptoms, the MTD of 
VNP20009 in humans was estimated to be 3.0×108 cfu/
m2. Adverse reactions at higher doses included fever, 
hypotension, anemia and thrombocytopenia and were 
probably due to cytokine release. Despite VNP20009 
attenuation, significant amounts of TNF were detected 
in the patients’ peripheral blood. Most adverse effects 
were mild and rapidly reversible, but none of the 25 pa-
tients experienced objective cancer regression. Bacteria 
were rapidly cleared from the peripheral blood and tu-
mor colonization by Salmonella could be detected only in 
three patients (Toso et al., 2002). This result was clearly 
in contrast with data from the murine tumor models.
In a subsequent clinical study, additional 4 patients 
with metastatic melanoma received a 4-hour intravenous 
infusion of VNP20009 at the MTD of 3.0 × 108 cfu/m2. 
Adverse effects of the treatment included fever, chills 
and nausea, but were minor and transient. VNP20009 
was detectable in samples of patients’ blood up to 2 
hours post treatment. No Salmonella could be cultured 
from tumor biopsies taken within 2 weeks of therapy 
(Heimann & Rosenberg, 2003).
The results of VNP20009 phase I clinical trials did 
not confirm Salmonella accumulation and tumor regres-
sion similar to previous preclinical data. However, the 
important finding is that VNP20009 can be safely ad-
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ministered to humans in large doses and that the toxicity 
of this bacterial strain is limited. Moreover, the first-in-
man study revealed that low tumor targeting in humans 
is a crucial therapeutic drawback of VNP20009. Since 
this feature can be significantly improved using genetic 
engineering, we made an attempt to enhance the accu-
mulation of Salmonella in human tumors by constructing 
a VNP20009 strain expressing single chain antibody frag-
ments specific to the carcinoembryonic antigen (CEA; 
Fig. 1). This VNP derivative was able to efficiently tar-
get CEA-expressing tumors in mice and could possibly 
overcome the targeting limitations of VNP20009 in hu-
mans, since CEA is present on more than 50% of hu-
man carcinomas (Bereta et al., 2007).
In summary, bacterial cancer therapy has recently 
moved beyond an interesting concept and has by now 
been supported by solid preclinical and clinical data. The 
unique features of bacterial therapeutics create the op-
portunity for novel anticancer strategies as bacteria meet 
all requirements for an ideal tumor-targeting agent. While 
the mechanism of action is often unclear, many examples 
have already proved that cancer treatment with bacteria 
can be site-specific, highly focused on the tumor and 
safe to other tissues. Among bacterial strains evaluated 
as cancer therapeutics so far, Salmonella Typhimurium is 
one of the most promising with first-in-man studies that 
support feasibility of clinical application. However, excel-
lent tumor colonization observed in murine models was 
not confirmed in humans, suggesting that tumor target-
ing is the major obstacle for further development. As 
Table 4. Applications of S. Typhimurium as a vaccine vector
Plasmid containing: Promoter Salmonella strain Tumor
Mouse 
strain Route* P/T** References
Beta-galactosidase (β-gal) CMV SL7207 β-gal
+-F1A11 
fibrosarcoma Balb/c O P (Paglia et al., 1998)
MG7-Ag-mimotope-PA-
DRE (Th-epitope)
CMV SL3261 Ehrlich ascites carcinoma Balb/c O P (Guo et al., 2003)
MG7-Ag-mimotope-
HBcAg CMV X4550
Ehrlich ascites 
carcinoma Balb/c O P (Meng et al., 2005)
mAFP CMV Not stated
CT26-mAFP
colon carcinoma
Hepa1-6 hepa-
toma
Balb/C
C57J/L O P (Chou et al., 2006)
SopE-NY-ESO-1*** Psop ΔphoP ΔphoQ CMS5a sarcoma Balb/c OIT T (Nishikawa et al., 2006)
Tyrosine hydroxylase 
epitopes-Ub CMV SL7207
NXS2 neurobla-
stoma A/J O P + T (Huebener et al., 2008)
Survivin epitopes-Ub CMV SL7207 NXS2 neurobla-stoma A/J O P + T (Fest et al., 2009)
SopE-Hsp70-Trp2 Psop SL3261 B16F10 mela-noma C57BL/6J O P + T (Zhu et al., 2010)
SseF-CO-Survivin****
+ STAT3shRNA PsseA MVP728 YS1646
B16F10 mela-
noma C57BL/6 O T (Manuel et al., 2011)
mPSCA CMV SL7207 TRAMPC1 pro-state carcinoma C57BL/6 O P (Ahmad et al., 2011)
YopE-VEGFR2 Plac SB824 B16F10 mela-noma C57Bl/6 OG P (Jellbauer et al., 2012)
Endoglin CMV SL7207
B16F10 mela-
noma
Renca renal 
carcinoma
C57Bl/6
Balb/c O P + T (Jarosz et al., 2013)
*O, oral; OG, orogastric; IT, intratumoral; **P, prophylactic-, T, therapeutic approach; ***underlined, Salmonella protein fragments serving as secre-
tion signals; ****CO, codon optimized.
figure 1. Tumor targeting of Salmonella via the anti-ceA anti-
body fragment. 
(A) a single chain antibody fragment (scFv) specific to carcinoem-
bryonic antigen (CEA) was derived from a CEA-specific immu-
noglobulin G molecule; (B) A DNA sequence encoding scFv was 
fused with the gene coding for OmpA, an outer membrane pro-
tein of E. coli, and expressed in VNP20009, an attenuated strain of 
Salmonella Typhimurium.
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many researchers focus on the effector molecules and 
other antitumor features of S. Typhimurium, insufficient 
localization in human tumors remains to be an unsolved 
issue. Targeting based on an antibody-fragment specif-
ic to TAAs is one of the few approaches proposed to 
overcome this drawback of therapeutic Salmonella strains.
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